Yazılar

AstraZeneca Signs $5.3 Billion AI Research Deal with China’s CSPC to Develop Chronic Disease Therapies

/in /tarafından

AstraZeneca has entered into a significant AI-driven research partnership with China’s CSPC Pharmaceutical Group worth up to $5.3 billion. The agreement aims to advance the development of therapies targeting chronic diseases, reinforcing AstraZeneca’s commitment to innovation in its second-largest market.

Under the collaboration, CSPC will conduct AI-led research in Shijiazhuang City to discover and develop pre-clinical candidates, including a small molecule oral therapy for immunological diseases. AstraZeneca will pay CSPC an initial upfront fee of $110 million and can receive up to $1.62 billion in development milestone payments, plus an additional $3.6 billion tied to sales milestones.

This partnership follows AstraZeneca’s broader efforts to strengthen its presence in China, including a $2.5 billion investment in a new R&D hub in Beijing announced earlier this year. It also builds on recent collaborations with AI-focused companies like Immunai, Qure.ai, and Tempus AI.

The deal also grants AstraZeneca rights to exclusive licenses for drug candidates identified through the joint research. This adds to a previous licensing deal signed in October, where AstraZeneca agreed to pay up to $1.92 billion to CSPC to enhance its cardiovascular drug pipeline.

CSPC, which derives about 80% of its revenue from finished drugs, is currently exploring additional licensing and collaboration opportunities, according to Morningstar analysts.

Sharon Barr, AstraZeneca executive, highlighted the collaboration as part of the company’s commitment to tackling chronic diseases affecting over two billion people worldwide.

Merck Strikes $2 Billion Deal with Hansoh Pharma for Oral Weight-Loss Drug

/in /tarafından

Merck (MRK.N) has entered a licensing agreement worth up to $2 billion with Chinese biotech firm Hansoh Pharma (3692.HK) for the development of an experimental oral weight-loss drug, HS-10535. This move positions Merck as a new competitor in the race to deliver an alternative to injectable weight-loss treatments.

Details of the Agreement

Under the agreement, Merck will assume responsibility for developing, manufacturing, and commercializing the drug. Hansoh’s HS-10535 is a GLP-1 receptor agonist candidate, designed to emulate the effects of injectable weight-loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro.

Merck will pay Hansoh an upfront fee of $112 million for the exclusive license, with potential milestone payments of up to $1.9 billion based on development, regulatory progress, and sales achievements. Hansoh will also receive royalties on future sales.

Competitive Landscape

Merck faces stiff competition in the burgeoning weight-loss market. Its oral drug candidate will likely trail behind rivals such as Eli Lilly’s orforglipron, which is further along in development. Other pharmaceutical giants, including Pfizer, Amgen, and Structure Therapeutics, are also testing oral obesity treatments, while AstraZeneca has partnered with China’s Eccogene on a similar initiative.

HS-10535 is currently in the preclinical testing phase, focusing on animal studies, meaning it could be several years before it reaches commercial availability. However, Merck sees potential in the drug not only for weight loss but also for delivering cardiometabolic benefits, according to Merck Research Laboratories president Dean Li.

Merck’s Broader Strategy

This deal reflects Merck’s broader focus on second- and third-generation weight-loss treatments, particularly oral solutions that may offer added convenience over injectables. Beyond HS-10535, Merck is also developing efinopegdutide, a GLP-1 candidate targeting metabolic dysfunction-associated steatohepatitis (MASH), a severe fatty liver disease associated with obesity.

Despite entering the weight-loss race later than its competitors, Merck aims to carve a niche in the field by emphasizing treatments that address obesity-related conditions alongside weight reduction.

Market Response and Implications

Shares of Merck rose slightly to $100.80 in premarket trading following the announcement. Analysts, however, expressed concerns about the timing, as Merck’s drug will likely lag behind more advanced contenders.

Weight-loss treatments, particularly GLP-1 receptor agonists, are shaping up to be a multibillion-dollar market, driven by increasing global demand for effective and convenient solutions to obesity. The licensing deal with Hansoh signifies Merck’s commitment to becoming a key player in this competitive market.

 

FDA Approves AstraZeneca’s Imfinzi for Limited-Stage Small Cell Lung Cancer

/in /tarafından

The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s immunotherapy drug Imfinzi (durvalumab) for treating certain adults with limited-stage small cell lung cancer (SCLC). The approval applies to patients whose disease has not worsened following chemotherapy and radiation therapy, the regulator announced on Wednesday.

Imfinzi, a human monoclonal antibody, functions by inhibiting cancer cells’ ability to evade the immune system. It also enhances the body’s natural anti-cancer response, providing a less toxic alternative to traditional chemotherapy.

Clinical Evidence and Significance

In a late-stage clinical trial, Imfinzi demonstrated a statistically significant improvement in overall survival compared to a placebo. This breakthrough offers hope for patients with limited-stage SCLC, a highly aggressive form of lung cancer known for its rapid progression and poor long-term prognosis. Only 15% to 30% of patients typically survive beyond five years following diagnosis.

Small cell lung cancer poses a significant challenge in oncology due to its recurrence and resistance to treatment. The approval of Imfinzi adds to the arsenal of targeted therapies aimed at improving survival rates for this difficult-to-treat condition.

Broader Use of Imfinzi

Imfinzi is already approved for treating multiple cancer types, including extensive-stage small cell lung cancer, bile duct cancer, and non-small cell lung cancer. Its latest approval for limited-stage SCLC underscores its expanding role in oncology and AstraZeneca’s commitment to advancing cancer treatment.

This milestone reflects a broader shift in cancer care, emphasizing immunotherapy’s potential to transform survival outcomes for patients with challenging diseases.